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Abstract
Background—The performance characteristics of spiral enteroscopy have not been well-
described.
Objective—To determine the technical performance, diagnostic and therapeutic yields, and
safety of oral spiral enteroscopy in patients with suspected or established small-bowel pathology.
Design—Prospective, multicenter, cohort study, with centralized database.
Setting—Ten U.S. tertiary-care medical centers.
Patients—This study involved 148 participants, of whom 101 were referred for obscure
bleeding. All participants referred for antegrade deep enteroscopy were considered eligible.
Intervention—Spiral enteroscopy.
Main Outcome Measurements—Examination duration, depth of insertion, spiral enteroscopy
findings, mucosal assessment upon withdrawal, and patient symptom assessment (day 1 and day 7
after the procedure).
Results—Spiral enteroscopy was successful in 93% of patients, with a median depth of insertion
beyond the angle of Treitz of 250 cm (range 10–600 cm). The mean (± standard deviation) total
procedure time was 45.0 ± 16.2 minutes for all procedures, and 35.4 minutes for diagnostic
procedures. The diagnostic yield was 65%, of which 48% revealed more than one abnormality.
The most common findings were angiectasias (61.5%), inflammation (7.5%), and neoplasia
(6.8%). Argon plasma coagulation ablation accounted for 64% of therapeutic interventions.
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Limitations—This was not a randomized, controlled trial of deep enteroscopy modalities.
Conclusion—Spiral enteroscopy appears to be safe and effective for evaluation of the small
bowel. The procedure duration, depth of insertion, and diagnostic and therapeutic yields compare
favorably with previously published data on other deep enteroscopy techniques such as single-
balloon and double-balloon enteroscopy. Comparative studies are warranted. (Gastrointest Endosc
2010;72:992–8.)
The advent of deep enteroscopy has revolutionized the management of patients with mid-
small–bowel diseases. Since the introduction of double-balloon enteroscopy by Yamamoto
in 2001, two additional techniques have become available, single-balloon enteroscopy and
spiral enteroscopy.1–3 Double-balloon enteroscopy and single-balloon enteroscopy entail a
similar mechanism of advancement consisting of sequential bowel pleating by a push-pull
technique that uses a balloon-fitted overtube with or without a second balloon inserted over
the tip of a dedicated enteroscope.
In contrast, spiral enteroscopy, or rotational enteroscopy, uses a spiral or raised helix–fitted
overtube coupled with the enteroscope, advanced as a unit into the small bowel by
continuous rotation of the overtube in a manner similar to use of a corkscrew. An inner
sleeve allows the independent motion of the overtube from the enteroscope during
advancement and withdrawal. The main difference between balloon enteroscopy and spiral
enteroscopy is that the latter uses a more or less continuous pleating of the small bowel by a
clockwise rotation of the overtube rather than the push-pull technique of the former two
methods.4 Previous small studies have suggested that spiral enteroscopy allows
advancement into the small bowel more efficiently than do techniques using balloon-assisted
devices.5 The technical performance of spiral enteroscopy as well as the diagnostic and
therapeutic yields have not been rigorously studied.
The aims of the present study were to determine the performance, yield, and safety of oral
spiral enteroscopy in patients with suspected or established small-bowel pathology within
the framework of a prospective, multicenter study in the United States.
MATERIALS AND METHODS
Study design
The study design consisted of a prospective, multicenter investigation of antegrade spiral
enteroscopy yield and efficacy. A centralized database was used to collect data from patients
evaluated at participating U.S. centers with experience in balloon enteroscopy. Patients with
suspected or established small-bowel disorders referred for anterograde deep enteroscopy
were considered eligible for the study if they had a previous nondiagnostic upper and lower
endoscopy or if they had other objective evidence of small-bowel disease based on prior
capsule endoscopy or small-bowel radiological studies. Patients with histories of esophageal
stricture, varices, advanced cirrhosis, or coagulopathy were excluded. Per study protocol,
centers with an enrollment of fewer than 10 participants were not included in the analysis.
Research informed consent was obtained from all patients before the procedure.
Procedure and instruments
The spiral enteroscopy technique has been described.4 Each procedure was performed by a
two-physician team, consisting of two experienced gastroenterologists or one faculty
gastroenterologist and one gastroenterology fellow. One physician guided the enteroscope
while the other operated the overtube. All investigators had participated in or observed at
least 20 spiral enteroscopy procedures before the current investigation.
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The Discovery small-bowel overtube (DSB; Spirus Medical, Inc, Stoughton, Mass) was
used for all study procedures. The use of the DSB standard profile or DSB low-profile
system was determined based upon patient characteristics and physician preference. The
choice of enteroscope was made based upon site availability, including the Fujinon
diagnostic double-balloon enteroscope (EN-450TS; Fujinon, Inc, Saitama, Japan) or the
Olympus single-balloon enteroscope (SIF-Q180; Olympus Corporation, Tokyo, Japan).
All sites chose procedure sedation according to local standards and anesthesia guidelines for
individual patients. Mallampati scores were assessed by the anesthesia or gastroenterology
attending physician. The use of fluoroscopy was allowed at the discretion of the site
gastroenterologist.
Study endpoints
Procedure times—Study times were recorded by the study staff during each procedure,
with the total procedure time (enteroscope insertion to enteroscope removal) as the primary
time endpoint. The following time milestones were also measured: helix engagement of the
pylorus and duodenum, maximum overtube insertion, maximum enteroscope insertion, and
procedure termination. The times of each therapeutic intervention were recorded and
summed to facilitate calculation of the total therapy time. Interventions included vascular
lesion ablation, polypectomy, stricture dilation, and solution injection (eg, India ink). The
procedure-adjusted diagnostic time was defined as the total procedure time minus the total
therapy time, which was calculated on a per-participant basis.
Depth of insertion and procedure yields—The depth of maximum enteroscope
insertion was estimated for each case, based upon withdrawal or bowel unpleating in
sequential 10-cm increments, a variation on the technique described by May et al,6 and
estimated as total centimeters beyond the angle of Treitz. The overtube external helix
facilitates controlled advancement and withdrawal of the enteroscope, such that the bowel
slippage observed with balloon enteroscopy was not a factor in depth estimations. Procedure
success was defined as enteroscope advancement beyond the angle of Treitz.
The procedure diagnostic and therapeutic yields were calculated based upon procedure
findings and therapeutic interventions. Correlation with capsule endoscopy findings was
graded as definite, probable, or negative.
Safety and tolerance—The evaluation of mucosal changes was systematically performed
upon enteroscope and overtube withdrawal. Assessment of the mucosa upon withdrawal of
the enteroscope is standard, but for the most part, other studies have not commented on the
spectrum of iatrogenic mucosal or bowel-wall damage. Specific evaluation focused upon the
following anatomic regions: proximal and distal esophagus, gastric lesser curve, pylorus,
second duodenum, angle of Treitz, and small bowel. Enteroscopy-related trauma was graded
as none/mild, moderate, and mucosal disruption. The type and severity of side effects and
complications were assessed during and after the procedure as well as at postprocedure days
1 and 7 by telephone interview. Patients were specifically queried about throat discomfort,
difficult or painful swallowing, abdominal discomfort or distention, and ability to resume
normal activities after the procedure. Preprocedure assessment of chronic abdominal
symptoms by Rome III or other criteria was not performed.7
A centralized, standard database, with Web-based data entry was used. The database
included 185 fields within the categories of demographics, medical history, enteroscopy
indications, procedure efficacy, therapeutic interventions, mucosal trauma, patient follow-
up, physician experience, and impressions. Statistical analysis was performed with STATA
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9 (Stata Corporation, College Station, Tex). The study was approved by the institutional
review boards of each center.
RESULTS
A total of 149 participants with suspected or established small-bowel disorders were
enrolled at 10 U.S. centers from April 2008 through October 2008. The median age was 68.0
years (range 20–88 years), and 40% were male (n = 57). The current analysis included 141
patients who had complete data. In agreement with the study protocol, centers with an
enrollment of fewer than 10 participants at the time of study closure were not included in the
analysis; 3 participants (two centers) were thereby excluded, each of whom had an
uncomplicated study and usual procedure time (37, 45, and 51 minutes). Five procedures
were aborted before initiation or completion—two for medical indications and two in
patients with obstructive sleep apnea (the anesthesiologist recommended intubation, but the
participants declined). One case was instructive, wherein a previously undiagnosed, subtle
cervical web was encountered; the spiraling of the overtube helix did not facilitate
advancement but rather bowing of the overtube.
The enrolled patient population had a significant percentage of comorbidities, which reflects
the obscure GI bleeding population in the United States (Table 1). This included coronary
artery disease (36%), congestive heart failure (11%), chronic obstructive pulmonary disease
(14%), diabetes (32%), and hypertension (52%). Prior abdominal or pelvic surgery was
common, noted in 52% of participants. A documented history of intra-abdominal adhesions
was reported in 8.5% (n = 12) of patients. Although the condition was not exclusionary, no
patients with prior Nissen fundoplication were enrolled. The use of chronic anticoagulant
medication before the procedure was common, including aspirin (27%), clopidogrel (12%),
warfarin (6.4%), and nonsteroidal anti-inflammatory drugs (5.6%). The mean (± standard
deviation [SD]) patient body mass index was 28.8 ± 9.0 kg/m2, with a range of 15.6 to 69.4
kg/m2.
Procedure indications
Obscure GI bleeding was the indication for deep enteroscopy in nearly three-fourths of
patients (n = 101, 72%). Of those cases with obscure GI bleeding, 32% were overt and 68%
occult (stool occult blood test positive or iron deficiency anemia). Two-thirds of this obscure
GI bleeding cohort (n = 67) had received transfusions within 6 months of the procedure.
Prior diagnostic evaluations included EGD (83%), colonoscopy (89%), push enteroscopy
(26%), and balloon enteroscopy (8.5%) (Table 2). The majority of participants (n = 113) had
undergone capsule endoscopy before enrollment, and 79% had abnormal results. Abnormal
imaging results also were a common indication for spiral enteroscopy, including abdominal
CT (n = 22), small-bowel follow-through (n = 5), and other imaging (n = 8). There were no
documented prior diagnostic or therapeutic angiography evaluations.
Procedure efficacy
Spiral enteroscopy was successful in 93% (132 of 142) of cases, with advancement beyond
the proximal jejunum and the presumptive extent of push enteroscopy. In 6 cases, only the
proximal jejunum was accessed, and in 4 cases, the angle of Treitz could not be reached,
including the patient with the cervical web. The use of fluoroscopy was limited to 16 cases
(11%). The standard profile DSB overtube was used in nearly all cases (93%). The Olympus
and Fujinon enteroscopes were used in 68% and 32% of cases, respectively, according to
site availability and preference. Most procedures were performed with patients under
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moderate conscious sedation with a combination of midazolam, fentanyl, or meperidine and
propofol administered either by an anesthesiologist or qualified endoscopy nursing staff.
The median depth of insertion beyond the angle of Treitz, estimated as described in
Materials and Methods, was 250 cm (mean ± SD = 250.3 ± 94.6 cm; range 10–600 cm). The
frequency plot of depth estimations demonstrates a gaussian distribution, an expected result
given variable patient anatomy and also arguing against significant bias in the depth
estimations (Fig. 1). The terminal ileum was reached in one case, in a patient with a Roux-
en-Y anastomosis with an estimated 100 cm of small bowel excluded.
The median total procedure time was 43.0 minutes (range 21–104 minutes). The mean
therapeutic intervention time was 11.4 minutes (range 0–73 minutes). The mean (± SD)
adjusted diagnostic procedure time for all procedures was 34.4 ± 10.1 minutes, calculated
for each patient. Importantly, this estimation was in agreement with the total procedure time
in nontherapeutic cases (35.4 minutes, n = 12). The mean (± SD) times to helix engagement
beyond the pylorus, maximum DSB overtube insertion time, and maximum enteroscope
insertion time were 8.4 ± 5.9 minutes, 22.1 ± 11.5 minutes, and 25.7 ± 12.1 minutes,
respectively.
Diagnostic and therapeutic yields
Abnormalities were detected at spiral enteroscopy in 65.2% (n = 92) of the evaluations, of
which 44% were felt to be definite findings and 21% probable findings (Table 3). The most
common diagnostic findings in those with positive study results included vascular ectasias
(56.2%), inflammation (15%), and neoplasia (7.9%). For study purposes, inflammation
included erosions, ulcerations, and/or mucosal changes suggestive of Crohn’s disease, such
as thickened or denuded villi, mucosal erythema and edema, or fold thickening with or
without associated strictures. The majority of these diagnostic findings were found in the
mid-jejunum (48 of 82). The correlation with capsule endoscopy findings, according to
protocol grading, was 40% definite, 32% probable or possible, and 28% negative. Ablation
with argon plasma coagulation of vascular ectasias accounted for the majority (64%) of
therapeutic interventions. Resection of polyps and mucosal biopsy were performed in 16%
of patients.
Procedure-related mucosal changes
Systematic assessment of mucosal changes related to the enteroscope and DSB overtube in
each segment of the small bowel and intestines was performed upon withdrawal. Mucosal
changes were limited in the majority of procedures (Table 4). Mucosal disruption was noted
in 8 cases, including small intestine (2), duodenum (1), pylorus (3), and proximal esophagus
(2). There were no perforations. The areas in which the mucosal changes occurred were
consistent among centers and operators, as assessed by significant erythema and mucosal
disruption (angle of Treitz, pylorus, esophagus).
Adverse events and side effects
Physicians judged the overall procedure as well-tolerated (77%), fairly well-tolerated
(14.5%), or average (5%). A small number (3.5%) of cases were poorly tolerated.
Significant symptoms during the procedure were limited but included agitation (1.4%),
significant cough (1.4%), and transient stridor (2%). One transient intussusception of the
pleated bowel was observed, with rapid resolution by gentle manipulation of the bowel by
using the enteroscope.
The most common procedure side effects at 24 hours included sore throat (28.3%) and/or
swallowing discomfort (24%) and abdominal bloating or discomfort (19%). Residual side
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effects at 7 days included sore throat (0.7%), swallowing discomfort (2.2%), and abdominal
bloating or discomfort (6.7%). There were no serious adverse events recorded such as
perforation, pancreatitis, ileus, or death. Ten office visits were recorded during the week
after the spiral enteroscopy.
DISCUSSION
Our study shows that spiral enteroscopy is a safe and effective deep enteroscopy technique.
The mean procedure time (mean endoscope insertion to removal time) of 45 minutes
compares favorably with the other deep enteroscopy approaches.8–13 In the U.S. multicenter,
double-balloon enteroscopy study, the mean procedure duration was 92.1 ± 37 minutes (n =
114).9 In particular, the time to maximal advancement of the enteroscope (mean 25.7 ± 12
minutes) is efficient, suggesting that the continuous pleating of the small bowel by using a
clockwise rotation of the helix overtube may be a more efficient advancement method than
the push-pull technique used with balloon-assisted enteroscopy. As noted, the terminal ileum
was reached in one patient with a gastric bypass, suggesting efficient pleating of the small
bowel. We acknowledge that our depth of insertion estimation method has not been
adequately validated, and therefore a comparison with historic cohorts may not represent an
adequate control group.
The diagnostic and therapeutic yields of the procedures in this study compare favorably with
data previously published regarding balloon-assisted enteroscopy. As anticipated in these
patient populations, the most common indication for spiral enteroscopy was obscure GI
bleeding, and the most common finding was vascular malformations. It is worth mentioning
that all endoscopists participating in this study had previously performed balloon-assisted
enteroscopies, yet the overall impression was that spiral enteroscopy was a very stable
platform for interventions such as cautery, biopsy, polypectomy, or solution injection. One
potential technical limitation with the single-balloon enteroscopy device is that air can
escape from the bowel distal to the enteroscope through the space between the endoscope
shaft and the overtube. This was not thought to be the case with spiral enteroscopy because
of the locking device in the overtube handle. Clearly, more comparative studies are required
to further elucidate the performance aspect of this procedure. The aims of the present study
were to determine the performance and yield of spiral enteroscopy in the small bowel.
Therefore, the prevalence of significant findings within the reach of standard endoscopy
(such as stomach, duodenum, or colon) was not consistently reported.
Despite the high prevalence of serious comorbid conditions including chronic obstructive
pulmonary disease, coronary artery disease, congestive heart failure, and diabetes, the
procedure was well-tolerated by the majority of patients, with a relatively limited incidence
of side effects such as sore throat, dysphagia, or odynophagia. There were no serious
complications such as pancreatitis, perforation, bleeding, or infection. The incidence of
significant mucosal trauma was measureable (8 mucosal disruptions were noted), in contrast
to the experience in the U.S. double-balloon enteroscopy study of similar design, which
included one mucosal tear.9 It was observed that the mucosal changes in the esophagus were
often related to the depth of sedation at procedure initiation. Only one patient could not be
intubated with the overtube, this because of an unrecognized cervical web. This compares
favorably with data published with alternative deep enteroscopy techniques.9,12,14–17
It is noteworthy that most procedures in the study were performed under deep sedation with
intravenous propofol. A small proportion of procedures were performed with the patient
under moderate sedation or general anesthesia. In the latter case, we noted that allowing the
endotracheal tube to deflate at the beginning of the procedure facilitates intubation of the
esophagus, with minimal resistance and minimal or no mucosal trauma.
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The prospective study design, with the use of a centralized database, strengthened the
validity of our study data. The patient population is representative of individuals with
obscure GI bleeding and, in general, patients in the United States requiring deep
enteroscopy. In addition, the evaluation of mucosal changes upon enteroscope withdrawal
was systematically performed to capture the spectrum of iatrogenic mucosal changes.
We acknowledge that this study was not a randomized trial with a comparative arm with
capsule endoscopy, push enteroscopy, or other deep-enteroscopy modalities. Assessment of
the learning curve was not included because all gastroenterologists had prior experience
with balloon enteroscopy and spiral enteroscopy. Although the study population was
representative of the U.S. obscure GI bleeding population, patients with upper GI strictures
and severe liver disease were excluded. We also were not able to evaluate long-term clinical
outcomes such as improvement or cessation of bleeding and survival. The study may have
had limited power to detect infrequent serious complications (eg, pancreatitis, perforation).
Last, this study did not evaluate retrograde spiral enteroscopy or spiral enteroscopy–assisted
ERCP.
What are the potential limitations of spiral enteroscopy (Table 5)? The procedure efficiency
is balanced by the overtube diameter (16 mm) in this “first generation” version of the
technology. This may increase the number of procedure-related mucosal changes and the
anesthesia requirements. We observed one patient who could not be intubated with the spiral
overtube because of a cervical web. The areas of procedural mucosal changes and mucosal
disruption were similar among centers, which suggests that these are expected “pressure
points” in spiral enteroscopy and that technique or overtube modifications and physician
experience may serve for prevention. In addition, the current spiral overtube technique
requires two operators—two gastroenterologists or a gastroenterologist and an assistant.
Importantly, latex allergy is not an issue with the spiral overtube.
In this initial study of spiral enteroscopy by endoscopists experienced in deep enteroscopy at
tertiary-care U.S. centers, spiral enteroscopy by the oral approach appears safe in selected
patients and can be used for diagnostic and therapeutic maneuvers in the mid-bowel and
possibly the proximal ileum. The performance and procedure duration appear comparable
with those of alternative deep-enteroscopy techniques. Further comparative prospective
studies are warranted to analyze outcomes such as procedure yields, transfusion burden, and
survival.
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• Spiral enteroscopy appears to be safe and effective for evaluation of the small
bowel. The procedure duration, depth of insertion, and diagnostic and
therapeutic yields compare favorably with other deep enteroscopy techniques
such as single-balloon and double-balloon enteroscopy. Comparative studies are
warranted.
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Spiral enteroscopy: small-bowel maximum depth of insertion beyond the ligament of Treitz
(LOT). Spiral enteroscopy was successful in 93% of cases, with advancement beyond the
proximal jejunum and the presumptive extent of push enteroscopy. In 4 patients, the angle of
Treitz could not be reached, including a patient with a cervical web. In 6 patients, the
examination was limited to the proximal jejunum. The maximum depth of insertion
estimates, expressed in centimeters, demonstrate a gaussian distribution, fulfilling criteria
for normality.
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TABLE 1
Spiral enteroscopy: patient medical and surgical history
Chronic medical condition No. of patients (%)
Coronary artery disease 51 (36.2)
Congestive heart failure 16 (11.4)
Chronic obstructive pulmonary disease 20 (14.2)
Hypertension 73 (51.2)
Diabetes 45 (31.2)
Crohn’s disease 6 (4.3)
Surgical history
 Cholecystectomy 25 (17.7)
 Appendectomy 24 (17.0)
 Hysterectomy 25 (17.7)
 Altered gastric anatomy 3 (2.1)
 Intestinal resection, colon or small bowel 9 (6.4)
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TABLE 2
Spiral enteroscopy: antecedent diagnostic evaluations
Diagnostic evaluation No. (%)
Endoscopy
 Capsule endoscopy 113 (79%)*
 Upper endoscopy 117 (83.0)
 Colonoscopy 124 (88.0)
 Push enteroscopy 37 (26.2)
 Balloon enteroscopy 12 (8.5)
Radiology
 Abdominal CT, abnormal result 22 (15.6)
 Small-bowel follow-through 17 (12.1)
 Enterography (CT, MR) 8 (5.7)
*
Eighty-nine of the 113 antecedent capsule endoscopy results were characterized as abnormal.













Morgan et al. Page 13
TABLE 3
Spiral enteroscopy: summary of small-bowel findings
Angiectasia Neoplasia Inflammation
Upper GI tract 21 3 6
Duodenum, distal 9 2 0
Jejunum
 Proximal 24 1 4
 Middle 33 0 6
 Distal 18 4 2
Ileum 4 2 2
Total 109 10 20
Upper GI tract includes findings in esophagus, stomach, and/or proximal duodenum. Inflammation refers to mucosal erythema, congestion,
thickened folds, thick or denuded villi, ulceration, erosions, and/or erythema. The characterizations of small- bowel segments are gross estimations
for lesion localization.
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TABLE 4
Spiral enteroscopy: mucosal changes
Erythema, none or minimal (%) Erythema, moderate (%) Mucosal disruption (no.)
Esophagus, proximal 85 15 2
Esophagus, distal 66 34 0
Gastric, lesser curve 93 6.7 1
Gastric, pylorus 75 25 3
Duodenum 80 20 0
Angle of Treitz 84 16 2
Small bowel 79 21 0













Morgan et al. Page 15
TABLE 5
Comparison of deep enteroscopy techniques, U.S. experience
Double balloon9*,12,15 Single balloon16,17 Spiral enteroscopy
Overtube material Latex Silicone PVC
 OD/ID, mm 13.2/10.8 13.2/11 16/9.8
 Length, cm 135 132 118
Sedation routine Deep, propofol Moderate, conscious Deep, propofol
Insertion depth, cm 218–370 132 250
Duration, minutes 68–101 38–49 45
PVC, Polyvinyl chloride; OD, outer diameter; ID, inner diameter.
*
The U.S. multicenter double-balloon enteroscopy study reported for antegrade double-balloon enteroscopy procedures a mean (± SD) insertion
depth of 370 ± 167 cm, with a mean (± SD) procedure duration of 90.3 ± 37 minutes.9
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